Stem Cell Therapy for Knee Pain & Osteoarthritis — What the Trials Show

Knee pain is one of the most common reasons people enquire about stem cell therapy. The claim — "regrow your cartilage" — gets repeated so often it sounds settled. The published evidence is more nuanced than that, and worth understanding before you spend SGD 18,000 on a knee injection.

Short version: mesenchymal stem cell (MSC) injections for knee osteoarthritis show a consistent, statistically significant signal for pain reduction and functional improvement across multiple randomised trials, but the evidence for actual cartilage regeneration is much weaker. The mechanism appears to be primarily anti-inflammatory and trophic rather than reconstructive. This still matters clinically — but it's a different value proposition than "growing back your knee".

What MSCs do in a joint

The mainstream understanding of how MSCs work has shifted substantially since the early 2000s. Arnold Caplan, who originally coined the term "mesenchymal stem cell" in 1991, has since proposed renaming them medicinal signalling cells, arguing that their primary therapeutic role is paracrine — secreting bioactive molecules that modulate inflammation and recruit local cells — rather than direct tissue replacement.^[1]

Inside an osteoarthritic joint, MSCs appear to:

Reduce local inflammation by secreting anti-inflammatory cytokines and prostaglandins.
Modulate the immune environment, dialling down the chronic low-grade inflammation that drives OA progression.
Stimulate resident chondrocytes (cartilage cells) to behave more anabolically.
Possibly contribute trophic factors that support local tissue repair.

What they probably don't do, at least not at clinically meaningful scale, is engraft and become new cartilage. Most studies that look for engraftment find very few cells survive long-term in the joint. The benefit is paracrine, not reconstructive.^[1]

What the RCTs actually report

The most useful place to start is Pas et al. (2017), a systematic review in the British Journal of Sports Medicine covering randomised and controlled trials of MSC injections for knee OA up to that date.^[2] The headline conclusion: there is moderate-quality evidence for symptomatic improvement (pain, WOMAC scores, KOOS scores) following MSC injection, with effects sustained out to 12 months. The authors note the trials are heterogeneous in cell source, dose, and outcome measures, and that more standardised RCTs are needed before strong clinical recommendations can be made.

The two most-cited individual trials worth knowing about:

Vega et al. (2015) — Transplantation

A randomised trial of bone-marrow-derived MSCs versus hyaluronic acid (HA) for knee OA, with 30 patients followed for 12 months. The MSC group showed significantly greater improvement in pain (VAS), function (Lequesne, WOMAC), and quality of life measures versus the HA control.^[3] MRI assessment showed some improvement in cartilage quality on T2 mapping, though structural cartilage thickness changes were modest.

Lamo-Espinosa et al. (2016) — Journal of Translational Medicine

A dose-escalation trial of autologous bone-marrow MSCs combined with hyaluronic acid for knee OA. The higher-dose group (40-million MSC) showed sustained pain and function improvement at 12 months that was statistically superior to HA-only control, with no serious adverse events.^[4] The authors framed the result as supporting a dose-response relationship — more cells, more benefit, up to a point.

Jo et al. (2014) — Stem Cells

A proof-of-concept trial using autologous adipose-derived MSCs in knee OA, with 18 patients across three dose tiers. The high-dose tier (100-million cells) showed significant improvement in WOMAC pain and function, with cartilage regeneration evident on second-look arthroscopy in some patients.^[5] Small sample, but historically important as the first dose-finding study with cartilage imaging endpoints.

"The pain and function data are real. The 'regrow your cartilage' marketing is mostly not."

What this means for a real patient

Translating these trials into a realistic expectation:

If you have early-to-moderate knee osteoarthritis (Kellgren-Lawrence grade 1-3) with persistent pain that hasn't responded to physiotherapy, weight management, and conservative anti-inflammatories — the MSC evidence is on your side. Expect meaningful pain reduction and functional improvement out to at least 12 months. Some patients see longer benefit; some see less.
If you have end-stage osteoarthritis (KL grade 4, bone-on-bone, severe deformity) — MSC therapy is unlikely to substitute for joint replacement. The evidence base in this group is much weaker, and the structural damage is past what paracrine signalling can address.
If you're an active 50-year-old with sports-induced cartilage wear and want to delay or avoid surgery — this is the population with the best alignment to the trial inclusion criteria. The published response is most consistent here.

How it's delivered

Joint MSC therapy is typically delivered as an intra-articular injection — directly into the joint capsule under ultrasound guidance — rather than as a systemic IV infusion. The cells are deposited where you want them to act. Some protocols combine with hyaluronic acid as a carrier; some use the cells alone.

For systemic conditions or when multiple joints are involved, IV infusion may be the right route, but for a single symptomatic knee, the intra-articular route has the strongest evidence and the most precise delivery.

What to ask the clinic

Five clinic questions, in order:

What's the cell source? Bone marrow, adipose, or umbilical cord — each has different evidence bases and processing requirements.
What's the dose? The dose-response data above suggests cell counts in the tens-of-millions are where the published response sits. Sub-million-cell "injections" are a different product.
Is it true MSCs or stromal vascular fraction (SVF)? SVF contains some MSCs but is not the same product as expanded, characterised MSCs. Be sure which one you're paying for.
Is the cell processing GMP-compliant? ISO Class 5 cleanroom and PIC/S GMP are the standards for cell viability and contamination control.
What's your published outcome data? A clinic that has tracked and published its joint-MSC outcomes is in a different category from one that hasn't.

The bottom line

The published evidence supports MSC injection as a meaningful symptomatic option for early-to-moderate knee osteoarthritis. Pain and function improvements are real, statistically significant across multiple RCTs, and sustained out to 12 months. The marketing claims of "regrowing cartilage" are not well supported — the mechanism is largely paracrine and anti-inflammatory rather than reconstructive.

For the right patient, that's still a clinically valuable option, particularly when the alternative is systemic anti-inflammatories, repeated steroid injections, or premature joint replacement. For end-stage OA, MSC therapy is not a substitute for surgery. The job is matching the right protocol to the right stage of the disease — which is exactly what a competent regenerative-medicine consult is for.

Beyond Hundred is a medical concierge coordination service. We do not provide medical diagnoses or treatment. The clinical content above is general educational material; individual treatment decisions should be made with a qualified physician based on your imaging, symptoms, and overall picture. All stem cell therapies are performed by licensed medical professionals at accredited partner clinics.

Sources

Caplan AI. (2017) "Mesenchymal Stem Cells: Time to Change the Name!" Stem Cells Transl Med 6(6):1445-1451.
Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. (2017) "Stem cell injections in knee osteoarthritis: a systematic review of the literature." Br J Sports Med 51(15):1125-1133.
Vega A, Martín-Ferrero MA, Del Canto F, Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, et al. (2015) "Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial." Transplantation 99(8):1681-1690.
Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, Bondía JM, Aquerreta JD, Andreu EJ, Ornilla E, et al. (2016) "Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II)." J Transl Med 14:246.
Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS, et al. (2014) "Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial." Stem Cells 32(5):1254-1266.